OMEROS CORP
Omeros Corporation (NASDAQ: OMER) is a biopharmaceutical company engaged in the development and commercialization of pharmaceutical products, with a primary focus on compounds and therapies directed toward complement pathway targets and alternative pathway mechanisms. The company's website is www.omeros.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What OMEROS CORP does
In the company’s own words
Omeros Corporation (NASDAQ: OMER) is a biopharmaceutical company engaged in the development and commercialization of pharmaceutical products, with a primary focus on compounds and therapies directed toward complement pathway targets and alternative pathway mechanisms. The company's website is www.omeros.com.
The company operates through a single reportable segment focused on the development and commercialization of its proprietary pharmaceutical pipeline. Omeros' core business involves the research, development, manufacturing, and commercialization of innovative drug candidates, with particular emphasis on monoclonal antibodies and small molecules targeting specific biological pathways relevant to serious diseases.
The company's primary asset is its Compound, referred to as zaltenibart or OMS906, which is a monoclonal antibody targeting MASP-3 (mannan-binding lectin-associated serine protease-3). This compound and related products represent the foundation of Omeros' clinical development programs and commercial strategy. The company has established intellectual property portfolios across multiple patent families covering various aspects of its therapeutic approaches and manufacturing processes.
Omeros maintains operations across multiple geographic markets and collaborates with contract manufacturers and research organizations to support its development and manufacturing activities. The company's business model centers on advancing its proprietary compounds through clinical development stages toward regulatory approval and eventual commercialization, while also exploring licensing and partnership opportunities to expand its reach and capabilities.
In October 2025, Omeros entered into a significant asset purchase and license agreement with Novo Nordisk Health Care AG, whereby Novo Nordisk acquired certain assets related to Omeros' programs, including intellectual property, regulatory submissions, manufacturing technology, and related materials. Under this transaction structure, Omeros retained certain rights through exclusive and non-exclusive licenses to background technology and know-how, positioning the company to continue participating in the development and commercialization of products derived from its research while leveraging Novo Nordisk's resources and commercial capabilities.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- SEATTLE, WA
- Fiscal year end
- December
- CIK
- 1285819
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns OMEROS CORP — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · OMEROS CORP’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do OMEROS CORP and its peers compare on margins and cash generation over ten years?”
- “Where did five years of OMEROS CORP's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in OMEROS CORP's last four quarterly filings that the numbers alone won't show?”